Sponsors / MNKD
MNKD

Mannkind Corporation

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
3Trials in this database
9Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Afrezza® INHALE-1 Study in PediatricsNCT04974528Mannkind CorporationPhase 3Completed2024-10-03Actual
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionNCT06418711Mannkind CorporationPhase 3Terminated2025-11-10Actual
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321Mannkind CorporationPhase 2Recruiting2027-03Estimated

Latest recorded trial changes

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711 · Mannkind Corporation

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

234 participants (planned)

+ After

132 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

1 Aug 2026

+ After

10 Nov 2025

Recruitment status changed

− Before

Recruiting

+ After

Terminated

Check registry source